{"id":"r-hirudin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2370450","moleculeType":"Unknown","molecularWeight":"2562.69"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"r-Hirudin is a recombinant version of hirudin, a naturally occurring anticoagulant from leech saliva. It binds directly and irreversibly to thrombin (Factor IIa), the key enzyme in the coagulation cascade, preventing thrombin from cleaving fibrinogen into fibrin and thus inhibiting clot formation. Unlike heparin, it does not require antithrombin III as a cofactor and provides more predictable anticoagulation.","oneSentence":"r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:31.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Thromboembolism prevention"}]},"trialDetails":[{"nctId":"NCT05847205","phase":"PHASE4","title":"Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2022-11-24","conditions":"Prophylaxis of Deep Vein Thrombosis","enrollment":100},{"nctId":"NCT01960569","phase":"PHASE4","title":"Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2013-10","conditions":"r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Thrombexx"],"phase":"marketed","status":"active","brandName":"r-Hirudin","genericName":"r-Hirudin","companyName":"MinaPharm Pharmaceuticals","companyId":"minapharm-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin. Used for Acute coronary syndrome, Thromboembolism prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}